SLC16A1 and myocarditis: Examples include pretreating CAR-T cells with succinate to enhance their efficacy (Ma et al., 2025), or using MCT1 inhibitors to modulate the production of pathogenic antibodies by B cells (Chi et al., 2024), offering novel avenues for treating cardiovascular conditions such as myocarditis.